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Background and Aims. Bloodstream infections (BSIs) are one of the most frequently observed hospital-acquired infections (HAIs).
We sought to describe the epidemiology and drug resistance secondary Enterobacterales BSIs in surgical patients and check for any
correlation with the type of hospital ward.Materials and Methods. )is multicenter (13 hospitals in southern Poland) laboratory-
based retrospective study evaluated adults diagnosed with BSI secondary to surgical site infection (SSI) hospitalized in 2015–2018;
121 Enterobacterales strains were collected. )e drug resistance was tested according to the EUCAST recommendations. Tests
confirming the presence of extended-spectrum β-lactamases (ESBLs) and bla resistance genes were carried out. )e occurrence of
possible clonal epidemics among K. pneumoniae strains was examined. Results. )e prevalence of Enterobacterales in secondary
BSI was 12.1%; the most common strains were E. coli (n� 74, 61.2%) and Klebsiella spp. (n� 33, 27.2%). High resistance involved
ampicillin and ampicillin/sulbactam (92, 8–100%), fluoroquinolones (48–73%), and most cephalosporins (29–50%). Carbape-
nems were the antimicrobials with the susceptibility at 98%. )e prevalence of ESBL strains was 37.2% (n� 45). All the ESBL
strains had blaCTX-M gene, 26.7% had the blaSHV gene, and 24.4% had blaTEM gene.)e diversity of Klebsiella strains was relatively
high. Only 4 strains belonged to one clone. Conclusions. What is particularly worrying is the high prevalence of Enterobacterales in
BSI, as well as the high resistance to antimicrobial agents often used in the empirical therapy. To improve the effectiveness of
empirical treatment in surgical departments, we need to know the epidemiology of both surgical site infection and BSI, secondary
to SSI. We were surprised to note high heterogeneity among K. pneumoniae strains, which was different from our
previous experience.
1. Introduction
In recent years, data concerning the epidemiology of
bloodstream infections (BSI) have indicated a change in the
prevalence of their microbial etiological agents. Gram-
negative pathogens are predominant as the major causes of
bacteremia, and according to researchers, the proportion of
Escherichia coli increased by 33% and amounted to as many
as ¼ of all pathogens and among patients of over 75 years of
age, even by over 30% [1]. Enterobacterales bloodstream
infection (BSI) is one of the most frequently observed
hospital-acquired infections (HAIs), especially in surgical
patients. All over the world, also in Poland, there are sig-
nificantly more secondary BSIs, a fact that calls for imme-
diate measures taken in order to prevent and control BSI in
adults.
In 1983, strains with the extended-spectrum β-lactamase
(ESBL) mechanism were first observed, and this phenotype
quickly became dominant among Gram-negative resistant
strains. Genes transmitted mainly by plasmids are respon-
sible for resistance to penicillins, cephalosporins, and
aztreonam, and their presence is also associated with
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resistance to antibiotics other than β-lactams, i.e., fluo-
roquinolones or aminoglycosides [2]. For more than twenty
years, an increase in the number of resistant strains and
infections with ESBL strains has been observed [2]. Wide-
spread use of inexpensive antibiotics such as cephalosporins
leads to the spread of ESBL strains in Europe and the USA
[3]. Among the ESBL strains, E. coli and Klebsiella pneu-
moniae most often cause BSI [2, 4].
Studies by Sakellariou et al. have shown that E.coli BSI is
most often of urological origin, whereas K. pneumoniae BSI
is associated with surgical site infection (SSI), respiratory
tract infection, or unknown infection [5]. Factors increasing
the risk of such infections include the presence of invasive
devices, especially vascular or indwelling catheters, age, ICU
stay, septic shock, stay in a nursing home, and previous
antibiotic therapy or inappropriate therapy [4, 6]. Antibiotic
therapy with third-generation cephalosporins, β-lactams,
and fluoroquinolones is particularly significant in the de-
velopment of the ESBL phenotype [4]. ESBL infections are
associated with increased mortality, costs, and prolonged
hospitalization [2]. In the case of ESBL-positive
K. pneumoniae, associated with surgical site infection, the
risk factors include peritonitis, the use of broad-spectrum
cephalosporins, neutropenia, septic shock, and ICU stay [7].
)e main purpose of this study was to determine the
drug resistance in Enterobacterales isolated from secondary
bloodstream infection in surgical patients. In this manu-
script, only cases of laboratory-confirmed bloodstream in-
fections (LC-BSIs) were subjected to analysis according to
the ECDC (European Centre for Disease Prevention and
Control) definitions, in which it is diagnosed when the
patient demonstrates at least one of the following symptoms:
fever (>38°C), chills, blood pressure drop, blood cultures
giving at least one positive result and a pathogenic micro-
organism is isolated, or two independent trials, up to 48
hours apart, give rise [8]. Additionally, the occurrence of
possible clonal epidemics among K. pneumoniae strains was
examined.
2. Materials and Methods
)is multicenter laboratory-based retrospective study in-
cluded 997 adult surgery patients (18≤) with LC-BSIs hos-
pitalized in southern Poland (13 hospitals).)e patients were
hospitalized in 15 surgery units of different types: general,
urology and vascular surgery wards, or gynecology and
obstetrics wards. )e qualifying criterion was to diagnose
secondary bloodstream infection, except for central or pe-
ripheral venous catheter BSI.
Altogether, 121 Enterobacterales strains were isolated.
Identification of microorganisms was performed using the
MALDI-TOF Biotyper (Bruker Corporation, the Nether-
lands) according to standard methods. )e isolates had been
collected retrospectively in collaboration with KORLAB
between 1 January 2015 and 31 December 2018 and the
Department of Microbiology at the Jagiellonian University
Medical College.
Antimicrobial susceptibility testing of all isolates was
performed according to the current guidelines of the
European Committee on Antimicrobial Susceptibility
Testing (EUCAST, http://www.eucast.org/
clinical_breakpoints/; accessed December 2017) by disc
diffusion on Müeller–Hinton agar plates. Resistance was
determined to six categories of antimicrobial agents: peni-
cillin (also with clavulanic acid and tazobactam), cephalo-
sporins (fourth-generation cefuroxime, ceftazidime,
cefotaxime, cefepime, and cefoperazone-sulbactam), car-
bapenems (ertapenem, imipenem, and meropenem), ami-
noglycosides (amikacin, gentamicin, and tobramycin),
fluoroquinolones (ciprofloxacin), and sulfamethoxazole
with trimethoprim.
ESBL activity was detected with a modified double disk
synergy test using a combination of cefotaxime, ceftazidime,
cefepime, and aztreonam discs, placed 20mm apart around a
disc containing amoxicillin/clavulanic acid [9].
All isolates with ESBL activity were screened with
multiplex PCR for the presence of blaTEM, blaSHV, and
blaOXA β-lactamase genes and for variants of blaCTX-M
β-lactamase genes (group including blaCTX-M-1, blaCTX-M-3,
and blaCTX-M-15, group 2 including blaCTX-M-2, and group 9
including blaCTX-M-9 and blaCTX-M-14) using previously
published primers [10]. Due to the largest number of ESBLs
among Klebsiella spp. being Klebsiella pneumoniae strains
(n� 27), pulsed-field gel electrophoresis (PFGE) was per-
formed to check for a clonal epidemic. Our previous ex-
periments showed that Klebsiella strains isolated in Polish
departments often belong to one clone. PFGE was used to
determine the possible horizontal transfer of K. pneumoniae
strains among patients from the same wards. Genomic DNA
was digested with 10 U XbaI (EURx, Gdańsk, Poland). )e
resulting DNA fingerprinting was obtained using the CHEF
III PFGE system (BioRad, Warsaw, Poland) in 0.5 Tris-
borate-EDTA buffer at 14°C at 6V for 22 h with a ramped
pulse time of 2–35 s. )e GelCompar (Applied Maths) was
used for cluster analysis using the Dice coefficient and the
unweighted pair group method with arithmetic mean.
3. Results
)emedian age (quartiles Q1 and Q3) was 67 years (59, 76),
and 63 (52.0%) patients were women. Most patients (47
persons, 38.8%) were hospitalized in general surgery wards.
In the range of less than 59 years, a higher number of cases
among women were observed compared to men (39.6% and
13.7%, respectively); while with age, there is an increase in
the number of cases among men (in the range of over 70
years: men 51.7%, women 26.9%).
)e prevalence of Enterobacterales in secondary BSI was
12.1%; the most common strain was E. coli (n� 74, 61.2%)
and Klebsiella spp. (33 patients, 27.2%), regardless of the
gender or age group (Table 1). In the genus Klebsiella, 27
Klebsiella pneumoniae, 5 Klebsiella oxytoca, and 1 Klebsiella
mobilis strains were identified. An inconsiderable percentage
of other species of Enterobacterales bacilli was 11.5%. In the
group designated “others,” 10 strains were Proteus mirabilis,
3 Enterobacter cloacae, and 1 Citrobacter freundii.
)e highest drug resistance was reported with regard to
ampicillin in association with sulbactam, reaching 100%
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(Table 2). High resistance also involved fluoroquinolones
(48–73%) andmost cephalosporins (29–50%). Only 1 (0.8%)
strain was fully sensitive, but 37 strains (30.6%) were re-
sistant to 5 or more antimicrobial categories studied (Ta-
ble 2). )e studied strains demonstrated almost full
sensitivity only to carbapenems (nearly 100% sensitivity),
and two strains (E. coli and Klebsiella pneumoniae) were
observed to be resistant to selected carbapenems.
)e prevalence of ESBL strains was 37.2% (n� 45). Most
ESBL-positive strains belonged to the genus Klebsiella
(n� 22; 66.7%) and were especially present in general sur-
gery wards (n� 175; 1.5%). Among E. coli, although they




E. coli n� 74 Klebsiella spp. n� 33 Others n� 14
Prevalence rate∗ (%) 7.4 3.3 1.4 12.1
Surgery wards
General ward 51 (68.9%) 27 (81.8%) 9 (64.3%) 87 (71.9)
Urology ward 19 (25.7%) 5 (15.1%) 3 (21.4%) 27 (22.3)
Gynecology and obstetrics ward 2 (2.7%) 1 (3.0%) 1 (7.1%) 4 (3.3)
Vascular ward 2 (2.7%) 0 (0.0%) 1 (7.1%) 3 (2.5)
Age range
≤59 22 (29.7%) 6 (18.1%) 5 (35.7%) 33 (27.3)
60–69 22 (30%) 16 (48%) 3 (21%) 41 (33.9)
70≤ 30 (40.5%) 11 (33.3%) 6 (42.8%) 47 (38.8)
Total 74 (61.1%) 33 (27.2%) 14 (11.5%) 121 (100)
∗Calculated by dividing the number of strains by the number of laboratory-confirmed bloodstream infections and multiplying by 100.
Table 2: Drug resistance in Enterobacterales bacilli in studied surgical wards.
Enterobacterales n� 121 (100%)
Nr category Antimicrobial category Antimicrobial agent E. coli n� 74(61.1%)




1 Penicillins and penicillins withinhibitors
Ampicillin 73 (98.6%) 33 (100%) 14 (100%)
Ampicillin-sulbactam 72 (97.2%) 33 (100%) 13 (92.8%)
Amoxicillin-clavulanic
acid 34 (45.9%) 20 (60.6%) 5 (35.7%)
Piperacillin-tazobactam 10 (13.5%) 11 (33.3%) 3 (21.4%)
2 Cephalosporins
Cefuroxime IV 29 (39.1%) 15 (45.4%) 7 (50.0%)
Ceftazidime 29 (39.1%) 14 (42.4%) 5 (35.7%)
Cefotaxime 28 (37.1%) 13 (39.3%) 5 (35.7%)
Cefepime 22 (29.7%) 16 (48.4%) 5 (35.7%)
Cefoperazone-sulbactam 6 (8.1%) 6 (18.1%) 0
3 Carbapenems
Ertapenem 0 1 (3.0%) 0
Imipenem 1 (1.3%) 0 0
Meropenem 0 0 0
4 Fluoroquinolones Ciprofloxacin 36 (48.6%) 24 (72.7%) 8 (57.1%)
5 Aminoglycosides
Gentamicin 19 (25.6%) 7 (21.2%) 5 (35.7%)
Amikacin 11 (14.8%) 13 (39.3%) 2 (14.2%)
Tobramycin 24 (32.4%) 17 (51.5%) 5 (35.7%)
6 Others Trimethoprim-sulfamethoxazole 37 (50.0%) 21 (63.6%) 9 (64.2%)
Nonsusceptible to antimicrobial categories∗
0 categories (fully
susceptible) 0 0 0
1 category 25 (33.7%) 5 (15.1%) 2 (14.2%)
2 categories 15 (20.2%) 6 (18.1%) 3 (21.4%)
3 categories 4 (5.4%) 4 (12.1%) 4 (28.5%)
4 categories 11 (14.8%) 4 (12.1%) 1 (7.1%)
5 categories 18 (24.3%) 14 (42.4%) 4 (28.5%)
6 categories 1 (1.36%) 0 0
∗Strains were divided into six categories based on their resistance to a specific number of antimicrobial agent categories (penicillin and penicillins with
inhibitors, cephalosporins, carbapenems, fluoroquinolones, aminoglycosides, and trimethoprim-sulfamethoxazole); fully susceptibility to all antimicrobial
agents from all categories means “0”; “6” means resistance to at least one antimicrobial agent from each of the 6 categories.
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constitute the majority of the Enterobacterales strains iso-
lated, ESBL strains were about ¼ (Table 3).
Among the ESBL (n� 45) strains, 12 strains (26.7%) had
the blaSHV gene (10 Klebsiella and 2 others), 11 strains
(24.4%) had blaTEM (6 Klebsiella, 3 others, and 2 E. coli), 14
strains (31.1%) had blaOXA (6 E. coli, 6 Klebsiella, and 2
others), and 45 strains (100%) had blaCTX-M (Table 3).
)e most common were blaCTX-M genes belonging to
group 1 (including blaCTX-M-1, blaCTX-M-3, and blaCTX-M-15)
up to 34 strains (75.5%), then variants of blaCTX-M group 9
(including blaCTX-M-9 and blaCTX-M-14) in 4 strains (8.9%),
and group 2 (including blaCTX-M-2) in one strain (2.2%).
Seven of the blaCTX-M genes belonged to groups other than
those tested.
)e result of PFGE, among the studied Klebsiella
pneumoniae strains, showed that only 4 strains that have
been derived from the same ward of general surgery
belonged to one clone. Other strains varied widely
(Figure 1).
4. Discussion
Enterobacterales infections are common in surgical wards,
but the presented data show that their prevalence depends
significantly on the type of surgery procedures. In the an-
alyzed population, they were most often identified in general
surgery and after urological procedures, while in other
populations, this type of etiology was rare.
According to Kolpa et al., the prevalence of Enter-
obacteriaceae in HAIs in patients after neurosurgical pro-
cedures was 25.8%, but mainly related to BSI cases, where
prevalence was as high as 29.8% [11]. Similar values (33%)
were obtained in pediatric cardiac surgery [12]. And as
expected, completely different results were obtained in
studies on infections in patients after urological procedures,
where Enterobacteriaceae in BSI constituted 67.9%. )e
strains from LC-BSI showed significant drug resistance.
)ey were highly susceptible only to ciprofloxacin, piper-
acillin-tazobactam (90%), meropenem, and gentamicin
(100%) [13].
According to Melzer et al., urinary catheters increase the
risk of severe bacteremia and should be used only when there
is a clinical indication [14]. Research results by Lillie et al.
confirm that one of the main reasons for the increase in BSI
is the use of urinary catheters, often unnecessary [15].
Probably, the best way to reduce the number of BSI among
urological patients is to reduce the indwelling catheters
utilization and shortening the urinary catheter use [16].
To improve the effectiveness of empirical treatment in
surgical departments, we need to know the epidemiology of
both surgical site infection and BSI secondary to SSI, in-
cluding the prevalence of their microbial etiological agents
and antibiotic resistance profiles. Our results indicate an
alarmingly high level of drug resistance in Enterobacterales
strains associated with secondary BSIs in surgery patients in
southern Poland. )is situation may affect the risk of
therapeutic failures in empirical therapy. Based on presented
data in studied population, effective empirical therapy is
possible only with cefoperazone-sulbactam or piperacillin-
tazobactam in combination with aminoglycosides or the use
of carbapenems, which is definitely unfavorable because it
carries a high risk of increasing resistance to carbapenems
among Enterobacterales which is already a big problem in
other European countries such as Romania, Greece, and
Italy [17]. In Poland, among E. coli and K. pneumoniae
strains, resistance to aminopenicillins, third-generation
cephalosporins, and fluoroquinolones is still a bigger
problem, which does not mean that we should not be afraid
of the appearance of carbapenem-resistant strains [18].
Fortunately, resistance to carbapenems in Enterobacterales
was not confirmed in our studies, as only one strain was
resistant to imipenem. However, the application of one of
the antibiotics from the group of β-lactams, carbapenems,
aminoglycosides, or fluoroquinolones may lead to cose-
lection resistance to several groups of antibiotics. )is is an
indication for the need to perform microbiological tests
concurrently with targeted therapy and to conduct precise
microbiological surveillance. Unfortunately, in Polish hos-
pitals, microbiological testing is underutilized and antibiotic
consumption is one of the highest in Europe [19]. On the
other hand, measures are required to implement appropriate
infection prevention and control procedures.
Despite the fact that no mechanisms of carbapenem
resistance have been found in our study, we still observe a
high level of ESBL-positive strains, especially in
K. pneumoniae. )is observation is consistent with re-
ports from the SENTRY Antimicrobial Surveillance
Program, which indicate a continuous and faster increase
in the share of ESBL-positive K. pneumoniae and E. coli
strains in various types of infections in hospitals in the US
[20]. In our 2011–2013 research, the presence of ESBL was
only slightly lower at 57% KP and 21.4% EC [21]. In
addition, ESBL strains isolated from newborns were re-
sistant to aminoglycosides and SXT as here. Molecular
characterization of the 45 ESBL-producing isolates
showed that all (100%) isolates were producing blaCTX-M-
type ESBLs, which represented most of all by groups
blaCTX-M-1, blaCTX-M-3, and blaCTX-M-15 (75.5%), which is
consistent with our other studies about ESBL strains in
southern Poland [21, 22].
Table 3: Prevalence of ESBL strains among Enterobacterales bacilli in studied surgical wards.
Studied isolates E. coli n� 74 (100%) Klebsiella spp. n� 33 (100%) Others n� 14 (100%) All isolates n� 121 (100%)
ESBL (yes, %) 19 (25.7%) 22 (66.7%) 4 (28.6%) 45 (37.2%)
General ward 15 (20.3%) 17 (51.5%) 3 (21.4%) 35 (28.9%)
Urology ward 3 (4.0%) 4 (12.1%) 1 (7.1%) 8 (6.6%)
Gynecology and obstetrics ward 1 (1.4%) 1 (3.0%) 0 (0%) 2 (1.6%)
Vascular ward 0 (0%) 0 (0%) 0 (0%) 0 (0%)
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Molecular studies suggest that both mechanisms (clonal
spread and plasmid transfer) are important since ESBL-
positive strains have a larger share of the outbreak than
others. )e abundance of ESBL-positive strains from ma-
terials (wound, blood) from surgical patients may also be
due to the aggressive broad-spectrum antibiotic policy. We
should not ignore the local prevalence of ESBL when drug
delivery algorithms are constructed.
Based on previous experience concerning research in Polish
hospitals, we know that clonal spread more often affects
Klebsiella pneumoniae strains than E. coli; hence, we have now
checked whether the high ESBL share among this species is not
associated with clonal outbreak [21, 23]. However, the diversity
of Klebsiella strains in PFGE was relatively high—only 4 strains
belonged to one clone.)is fact was different from our previous
experience; probably, the cases of infection in this study were
not associated with the horizontal transfer.
)e high prevalence of ESBLs among Enterobacterales
in hospital wards cannot be unambiguously associated
with a high percentage of ESBLs in the general
population, and studies conducted by Ny et al. among
volunteers in six European countries, including Poland,
showed a prevalence of 8% in the case of E. coli ESBL and
0% in K. pneumoniae ESBL among polish carriers in
Silesian Voivodeship [24].
In the light of the data presented, rapid implementation of
targeted treatment, especially based on sensitive and quick
diagnostic tests, is of particular importance for successful in-
fection treatment. In addition to species identification, more
and more commercially available kits for identifying bacteria
from blood by molecular methods are able to detect the most
popular resistance mechanisms, e.g., KPC, NDM, blaOXA-48,
and others. In Poland, there are currently no clear recom-
mendations on how to effectively implement this type of
procedure, and for many hospitals and laboratories, the costs of
modern tests may also be a barrier [25]. Our study has a few
limitations. It is generally assumed that E. coli and
K. pneumoniae BSI behave similarly, since such a combination
was commonly adopted in the literature. Clinical data regarding
















































Figure 1: Pulsed-field gel electrophoresis dendrogram of Klebsiella pneumoniae strains.
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only the in-hospital outcome. Previous history of hospitalization
was unknown, and we did not know if the patient had pre-
viously used antibiotics or had an underlying disease.
Data Availability
)e data used to support the findings of this study are
available from the Department of Microbiology of the
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du.pl and Jadwiga Wojkowska-Mach, jadwiga.wojkowska-
mach@uj.edu.pl). Data on drug resistance of strains are also
available in the KORLAB laboratory (Monika Pomorska-
Wesołowska monikapw@op.pl).
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[11] M. Kolpa, M. Wałaszek, A. Różańska et al., “Epidemiology of
surgical site infections and non-surgical infections in neu-
rosurgical polish patients-substantial changes in 2003-2017,”
International Journal of Environmental Research and Public
Health, vol. 16, no. 6, p. 911, 2019.
[12] R. Abou Elella, H. K. Najm, H. Balkhy, L. Bullard, and
M. S. Kabbani, “Impact of bloodstream infection on the
outcome of children undergoing cardiac surgery,” Pediatric
Cardiology, vol. 31, no. 4, pp. 483–489, 2010.
[13] E. Kolwijck, A. E. M. Seegers, S. C. M. Tops et al., “Incidence
and microbiology of post-operative infections after radical
cystectomy and ureteral stent removal; a retrospective cohort
study,” BMC Infectious Diseases, vol. 19, no. 1, p. 303, 2019.
[14] M. Melzer and C. Welch, “Does the presence of a urinary
catheter predict severe sepsis in a bacteraemic cohort?”
Journal of Hospital Infection, vol. 95, no. 4, pp. 376–382, 2017.
[15] P. J. Lillie, G. Johnson, M. Ivan, G. D. Barlow, and P. J. Moss,
“Escherichia coli bloodstream infection outcomes and pre-
ventability: a six-month prospective observational study,”
Journal of Hospital Infection, vol. 103, no. 2, pp. 128–133, 2019.
[16] T. M. Hooton, S. F. Bradley, D. D. Cardenas et al., “Diagnosis,
prevention, and treatment of catheter-associated urinary tract
infection in adults: 2009 international clinical practice
guidelines from the infectious diseases society of America,”
Clinical Infectious Diseases, vol. 50, no. 5, pp. 625–663, 2010.
[17] https://atlas.ecdc.europa.eu/public/index.aspx?
Dataset�27&HealthTopic�4.
[18] V. Jarlier, H. L. Diaz, O. E. Heuer et al., “Strong correlation
between the rates of intrinsically antibiotic-resistant species
and the rates of acquired resistance in gram-negative species
causing bacteraemia, EU/EEA,” Euro Surveillance, vol. 24,
no. 33, 2019.
[19] J. Wojkowska-Mach, B. Godman, A. Glassman et al., “An-
tibiotic consumption and antimicrobial resistance in Poland;
findings and implications,” Antimicrobial Resistance and
Infection Control, vol. 7, p. 136, 2018.
[20] M. Castanheira, J. C. Mills, S. E. Costello, R. N. Jones, and
H. S. Sader, “Ceftazidime-avibactam activity tested against
Enterobacteriaceae isolates from U.S. Hospitals (2011 to 2013)
and characterization of β-lactamase-producing strains,” An-
timicrobial Agents and Chemotherapy, vol. 59, no. 6,
pp. 3509–3517, 2015.
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“Molecular epidemiology, plasmid analysis, virulence, and
resistance of Escherichia coli isolated from neonatal intensive
care units in Poland,” Diagnostic Microbiology and Infectious
Disease, vol. 76, no. 4, pp. 542–545, 2013.
[23] A. Chmielarczyk, M. Pobiega, J. Wójkowska-Mach,
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